Hims & Hers GLP-1 review (2026): what changed after Novo, and who it's right for
Hims & Hers overhauled its entire GLP-1 program in 2026. Here is exactly what you get, what you pay all-in, and whether it makes sense for a woman navigating midlife weight gain.
Hims & Hers is a NYSE-listed telehealth company with one of the highest-traffic GLP-1 enrollment funnels in the US. In 2026 it matters primarily to women because of its March 2026 partnership with Novo Nordisk: it now offers brand-name Wegovy (oral and injectable) and Zepbound through an async telehealth model at rates that are genuinely competitive, especially when a Novo savings card applies. The trade-off is structural — it is an async-only platform (no video visits, no proactive clinician outreach), the membership fee is charged separately from medication, and it is not a menopause-care service. For midlife women who want GLP-1 access and do not need hormone therapy alongside it, it works. Women who want a clinician who understands hormonal weight gain alongside GLP-1 treatment will be better served by a menopause-focused platform.
What you will actually pay
| Plan | Monthly | Visit fee | Best for |
| Membership (separate from medication) | $149 | $0 (async only) | Required for any Hims medication — billed apart from drug cost |
| Oral Wegovy (semaglutide pill)most popular | from ~$249 | Bundled in membership | Women who want semaglutide without injections |
| Injectable Wegovy (semaglutide injection) | from ~$299 | Bundled in membership | Standard injectable semaglutide via Novo partnership |
| Zepbound (tirzepatide injection) | from ~$399 | Bundled in membership | Women who want tirzepatide — highest-efficacy GLP-1 available |
Estimated all-in cost: ~$4,776–$6,576/yr (medication + membership, brand-name at ongoing rates). With qualifying insurance and Novo savings card: can reduce to $1,788/yr (membership only) or less.
- ✓ Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) — not compounded
- ✓ Async process — no video visit required, fast enrollment
- ✓ Partnered with Novo Nordisk; can facilitate savings card for $0–$25/mo on medication
- ✓ NYSE-listed, established company — not a fly-by-night operation
- ✓ Oral Wegovy option for women who prefer not to inject
- ✓ Covers all 50 states
- ⚑ Membership fee ($149/mo) billed separately from medication — easy to underestimate total cost
- ⚑ Async-only: no video visits, no proactive clinical follow-up
- ⚑ Not a menopause-care platform — no HRT, no menopause-specific protocols
- ⚑ Compounded semaglutide no longer available for new patients as of March 2026
- ⚑ Not designed for women who want hormonal weight gain context alongside GLP-1 treatment
- ⚑ Higher total cost than compounded alternatives for women without qualifying insurance
What Hims & Hers is — and how it changed in March 2026
Hims & Hers (NYSE: HIMS) is one of the largest telehealth companies in the US, best known for men's hair loss and ED treatments but now generating significant revenue from a women's weight-loss program under the 'Hers' brand. For most of 2024–2025, that program was built on compounded semaglutide — the same molecule as Ozempic and Wegovy, prepared by compounding pharmacies at a fraction of the brand-name price.
That changed in March 2026. Hims settled a dispute with Novo Nordisk and exited compounded semaglutide for new patients. The platform now operates as a brand-name GLP-1 prescriber: oral Wegovy, injectable Wegovy, and Zepbound (tirzepatide), all through a partnership with the manufacturers. This is a meaningfully different product lineup.
What Hims offers in 2026
- Oral Wegovy (semaglutide pill): ~$249/mo medication + $149/mo membership = ~$398/mo all-in
- Injectable Wegovy (semaglutide autoinjector): ~$299/mo medication + $149/mo membership = ~$448/mo all-in
- Zepbound (tirzepatide injection): ~$399/mo medication + $149/mo membership = ~$548/mo all-in
- Novo Nordisk and Lilly savings cards can reduce medication cost to $0–$25/mo with qualifying commercial insurance
The membership is the line item that catches people off guard. It is $149/month, billed separately, regardless of what medication you take or whether you have a good month or a rough one. It covers the clinical platform — the async consultation, prescription management, and clinical messaging. It does not cover the medication.
The async model: what it means in practice
Hims uses an entirely asynchronous clinical model. You fill out a health questionnaire; a clinician reviews it and writes a prescription; the medication ships. There are no video appointments at intake, no required follow-up calls, and no proactive check-ins unless you message the team. This is the fastest and lowest-friction way to start a GLP-1 program.
The flip side is that asynchronous models work best when your situation is straightforward. Women with complex medical histories, multiple medications, or health conditions that interact with GLP-1 therapy benefit from a clinician who actively engages — not just reviews a questionnaire. For uncomplicated GLP-1 candidates, the async model is fine. For nuanced cases, it is a limitation.
Pricing math: what you actually spend per year
The honest all-in annual calculation:
- Oral Wegovy: ~$249/mo med + $149/mo membership = $4,776/yr
- Injectable Wegovy: ~$299/mo med + $149/mo membership = $5,376/yr
- Zepbound: ~$399/mo med + $149/mo membership = $6,576/yr
- With qualifying insurance + Novo savings card: membership only = $1,788/yr
The insurance scenario is the best deal by far. If your commercial insurance covers Wegovy and you qualify for the Novo Nordisk savings card, you could pay $0 on medication and $149/mo on membership — making your total cost $1,788/yr. This requires both commercial insurance coverage of the drug and eligibility for the savings card, which excludes Medicare, Medicaid, and government-funded plans.
How Hims compares for midlife women specifically
Perimenopause weight gain has a hormonal component that generic GLP-1 platforms do not address. Falling estrogen reduces insulin sensitivity and promotes visceral fat redistribution — and a clinician who understands this connection prescribes differently than one treating generic obesity. Hims does not offer hormone therapy; its clinical team is not specialized in menopause.
This does not mean Hims cannot help with weight loss — GLP-1 medications work regardless of whether the prescriber knows your hormonal status. But if you want integrated care — HRT discussed alongside GLP-1, dosing informed by menopausal physiology — Alloy or Midi Health are better fits.
What past users say
Reviews for Hims & Hers' weight-loss program generally reflect the async model: fast and easy to start, less consistent on follow-through. The most common positive is speed — users appreciate not needing appointments. The most common negative is the membership fee confusion — users discover after enrolling that medication and membership are separately billed.
Trustpilot and Reddit reviews for the post-March 2026 brand-name model are still accumulating. The compounded-era reviews (which dominated 2024–2025 traffic) describe a different product.
Frequently asked questions
Does Hims still offer compounded semaglutide?+–
No. Following its March 2026 settlement with Novo Nordisk, Hims & Hers exited compounded semaglutide for new patients. The platform now offers brand-name Wegovy and Ozempic exclusively through the Novo partnership, plus Zepbound (tirzepatide).
What does the Hims membership actually include?+–
The $149/month membership covers access to the clinical platform — the async consultation, clinical review, and prescription management. It is billed separately from whatever medication you receive. You pay the membership fee even if your insurance covers the medication cost.
Can I use my insurance with Hims for GLP-1 medications?+–
For brand-name Wegovy and Zepbound, Hims can facilitate Novo Nordisk and Lilly savings cards, which can reduce medication cost to $0–$25/month with qualifying commercial insurance. Hims itself does not bill insurance for the membership. The medication prescription can go through an external pharmacy if your insurance covers it there.
Is Hims good for perimenopause weight management?+–
Hims prescribes GLP-1 medications for weight management — which are effective for metabolic weight gain in perimenopause. What it does not offer is the menopause-specific care context: no HRT evaluation, no discussion of how estrogen decline affects GLP-1 response. For women who want GLP-1 treatment integrated with hormonal care, a menopause-specialized platform like Alloy or Midi Health is a better fit.
How long does it take to get started with Hims?+–
The async consultation typically takes 24–48 hours to complete. Medication is shipped after prescription approval, usually arriving within 3–7 business days. No video appointment is needed at any point in the process.